Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Arvinas, Inc., ARVN
Summary: Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
- Last Price: $48.79
- Price Change: $1.79, 3.81%
- Yearly Gain: 59.60%
- Market Cap: $2.68B
- P/E Ratio: -8.84
Here are 3rd party ratings for ARVN:
- TipRanks.com: Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 32% (80 out of 251)
What is the sentiment on the street regarding Arvinas, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in ARVN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ARVN before you decide to make any investment.
Click here for chart >>
Iovance Biotherapeutics, Inc., IOVA
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
- Last Price: $16.60
- Price Change: $0.83, 5.26%
- Yearly Gain: 131.52%
- Market Cap: $4.63B
- P/E Ratio: -7.98
Here are 3rd party ratings for IOVA:
- TipRanks.com: Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 32% (80 out of 251)
What is the sentiment on the street regarding Iovance Biotherapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in IOVA or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on IOVA before you decide to make any investment.
Click here for chart >>
Celldex Therapeutics, Inc., CLDX
Summary: CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
- Last Price: $48.23
- Price Change: $10.48, 27.76%
- Yearly Gain: 12.03%
- Market Cap: $2.64B
- P/E Ratio: -18.2
Here are 3rd party ratings for CLDX:
- TipRanks.com: Buy
- TradingView.com: Strong buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 32% (80 out of 251)
What is the sentiment on the street regarding Celldex Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CLDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CLDX before you decide to make any investment.
Click here for chart >>
Edgewise Therapeutics, Inc., EWTX
Summary: Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.
- Last Price: $17.04
- Price Change: $-0.24, -1.39%
- Yearly Gain: 80.51%
- Market Cap: $1.59B
- P/E Ratio: -10.85
Here are 3rd party ratings for EWTX:
- TipRanks.com: Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 32% (80 out of 251)
What is the sentiment on the street regarding Edgewise Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in EWTX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on EWTX before you decide to make any investment.
Click here for chart >>
Thanks for reading!